domperidone has been researched along with clozapine in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.06) | 18.7374 |
| 1990's | 6 (18.18) | 18.2507 |
| 2000's | 17 (51.52) | 29.6817 |
| 2010's | 8 (24.24) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrieux, M; Besançon, R; Giros, B; Martres, MP; Pilon, C; Schwartz, JC; Sokoloff, P | 1 |
| Bouthenet, ML; Giros, B; Martres, MP; Schwartz, JC; Sokoloff, P | 1 |
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Emms, F; Freedman, SB; Knowles, MR; Marwood, R; McAllister, G; Patel, S; Seabrook, GR | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Fang, X; Hu, Z; Levant, B; Min, J; Varady, J; Wang, S; Wu, X | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Bhatia, P; Brioni, JD; Chang, R; Donnelly-Roberts, DL; El Kouhen, O; Hakeem, AA; Henry, R; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martino, B; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Patel, MV; Stewart, AO; Terranova, MA; Uchic, ME; Wetter, JM | 1 |
| Brioni, JD; Chang, R; Cowart, MD; Darbyshire, JF; Donnelly-Roberts, DL; El-Kouhen, OF; Gintant, G; Hakeem, AA; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martin, R; Martino, BR; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Nelson, SL; Patel, MV; Rohde, JJ; Stewart, AO; Sullivan, JP; Terranova, MA; Uchic, ME; Wetter, JM | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Sen, S; Sinha, N | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Barr, JT; Jones, JP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Halliday, CA; Leonard, MN; Marriott, AS; Strange, PG | 1 |
| Omeljaniuk, RJ | 1 |
| Wang, HH; Xu, SF | 1 |
| Mol, CA; Schinkel, AH; van Deemter, L; Wagenaar, E | 1 |
| de Leon, J; Diaz, FJ; Josiassen, RC; Simpson, GM | 1 |
| Bastianetto, S; Danik, M; Mennicken, F; Quirion, R; Williams, S | 1 |
1 trial(s) available for domperidone and clozapine
| Article | Year |
|---|---|
Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Domperidone; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Middle Aged; Prolactin; Review Literature as Topic; Schizophrenia; Sex Characteristics | 2004 |
32 other study(ies) available for domperidone and clozapine
| Article | Year |
|---|---|
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Topics: Animals; Chlorides; CHO Cells; Cricetinae; Dopamine; Dopamine Agents; Dopamine Antagonists; Guanylyl Imidodiphosphate; Humans; Lithium; Lithium Chloride; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3; Sodium Chloride; Sulpiride; Transfection | 1992 |
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Topics: Amino Acid Sequence; Animals; Antipsychotic Agents; Base Sequence; Brain Chemistry; Cell Line; Cloning, Molecular; Cricetinae; DNA; DNA Restriction Enzymes; Dopamine; Guanylyl Imidodiphosphate; Molecular Sequence Data; Nucleic Acid Hybridization; Polymerase Chain Reaction; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Sequence Homology, Nucleic Acid; Tissue Distribution | 1990 |
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
Expression and pharmacological characterization of the human D3 dopamine receptor.
Topics: Animals; Binding, Competitive; Cells, Cultured; CHO Cells; Cricetinae; Dopamine; Dopamine Antagonists; GTP-Binding Proteins; Guanine Nucleotides; Humans; Potassium Channels; Rats; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3; Recombinant Proteins; Second Messenger Systems; Sulpiride | 1994 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach.
Topics: Algorithms; Binding Sites; Computational Biology; Crystallography, X-Ray; Databases, Protein; Humans; Kinetics; Ligands; Lipid Bilayers; Models, Molecular; Molecular Conformation; Mutation; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Solvents; Structure-Activity Relationship; Tetrahydronaphthalenes; Water | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
Topics: Animals; Benzamides; Binding Sites; Cell Line; Crystallography, X-Ray; Disease Models, Animal; Drug Evaluation, Preclinical; Erectile Dysfunction; Ferrets; Humans; Male; Models, Molecular; Molecular Structure; Oximes; Piperazines; Rats; Rats, Wistar; Receptors, Dopamine D4; Stereoisomerism; Structure-Activity Relationship | 2006 |
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.
Topics: Action Potentials; Administration, Oral; Animals; Benzamides; Biological Availability; Cell Line; Cyclic N-Oxides; Dogs; Erectile Dysfunction; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Haplorhini; Humans; In Vitro Techniques; Male; Patch-Clamp Techniques; Purkinje Fibers; Rats; Receptors, Dopamine D4; Structure-Activity Relationship | 2006 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
Topics: Aldehyde Oxidase; Aminoacridines; Chromatography, Liquid; Enzyme Inhibitors; Humans; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Oxidation-Reduction | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
D2 dopamine receptors in rat striatum are homogeneous as revealed by ligand-binding studies.
Topics: Animals; Binding, Competitive; Clozapine; Corpus Striatum; Domperidone; Loxapine; Male; Rats; Receptors, Dopamine; Sulpiride | 1988 |
Specific [3H]spiperone binding sites in the pituitary of rainbow trout (Oncorhynchus mykiss) and goldfish (Carassius auratus).
Topics: Animals; Binding, Competitive; Clozapine; Domperidone; Dopamine; Dose-Response Relationship, Drug; Goldfish; Oncorhynchus mykiss; Pituitary Gland; Spiperone | 1995 |
[Effect of D1 and D2 dopamine receptor antagonists on acupuncture analgesia].
Topics: Acupuncture Analgesia; Animals; Benzazepines; Clozapine; Domperidone; Dopamine D2 Receptor Antagonists; Electroacupuncture; Female; Haloperidol; Male; Pain Threshold; Rabbits; Receptors, Dopamine D1; Sulpiride | 1993 |
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Brain; Cell Line; Clozapine; Diffusion; Domperidone; Epithelium; Flunitrazepam; Haloperidol; Humans; Kidney; Kinetics; Loperamide; Male; Mice; Mice, Inbred Strains; Ondansetron; Phenytoin; Recombinant Proteins; Structure-Activity Relationship; Swine; Tissue Distribution; Transfection | 1996 |
Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation.
Topics: Animals; Anisoles; Antipsychotic Agents; Benzazepines; Butaclamol; Caspase Inhibitors; Cell Death; Cells, Cultured; Chlorpromazine; Clozapine; Domperidone; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Ginkgo biloba; Haloperidol; Hippocampus; Indans; Isoxazoles; Neurons; Neuroprotective Agents; Peptides; Piperidines; Plant Extracts; Propylamines; Raclopride; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptors, N-Methyl-D-Aspartate; Remoxipride; Risperidone; Sulpiride | 2006 |